Table 2 First-line antiretroviral treatment initiated in HIV-2 infected patients in 17 studies
From: Antiretroviral therapy response among HIV-2 infected patients: a systematic review
Study | Study period | Dual NRTI | 3 NRTIs | PI-based regimen | Boosted PI | |||
|---|---|---|---|---|---|---|---|---|
(Author, year) | Â | Therapy | Â | Â | Â | Â | Â | Â |
| Â | Â | Â | Â | LPV | NFV | IDV | SQV | Â |
Adje-Touré, 2003 [34] | 1998-2000 | Yes (n = 6) | Yes (n = 1) | No | Yes (n = 7) | Yes (n = 4) | No |  |
Van Der Ende, 2003 [29] | 1995-2001 | Yes (n = 0) | Yes (n = 2) | No | Yes (n = 1) | Yes (n = 14) | Yes (n = 3) | 80% boosted PI |
Mullins 2004$[39] | 1994-2003 | No | Yes (n = 2) | No | Yes (2 ) | Yes (n = 2) | Yes [3] | Ritonavir boosted PI (n = 2; 22%) |
Matheron, 2006 [40] | NR- 2004 | No | Yes (n = 14) | No | Yes (n = 17) | No | No | Ritonavir boosted PI (n = 23) |
Ndour, 2006 [41] | 1998-2004 | No | No | No | No | Yes (n = 35) | No | No |
Drylewicz, 2008 [12] | 1996-2006 | No | NR | Yes (n = 14) | Yes (n = 10) | Yes (n = 1) | No | Ritonavir-boosted PI (n = 24) |
Ruelle 2008 [42] | NR-2006 | No | Yes (n = 6) | Yes (n = 4) | Yes (n = 3) | Yes (n = 5) | Yes (n = 1) | 4 NRTIs (n = 1) Ritonavir-boosted PI (n = 10) |
Benard A, 2009 [28] | NR | No | No | Yes (n = 29) | No | No | No | Ritonavir-boosted (n = 29; 100%) |
Jallow, 2009 [31] | 2004-2009 | No | No | Yes (n = 20) | No | No | No | Ritonavir-boosted (n = 20; 100%) |
Gottlieb, 2009 [23] | 2005-NR | No | No | No | No | Yes (n = 22) | No | No |
Harries 2010 [17] | 2002-2008 | No | Yes (n = 1) | Yes (n = 17) | Yes (n = 35) | Yes (n = 12) | No |  |
Drylewicz 2010 [30] | 1997-2007 | No | Yes (n = 21) | NR | NR | NR | NR | PI = 193 Ritonavir-boosted (n = 84; 43%) |
Smith 2010 [43] | NR | No | Yes (n = 1) | Yes (n = 0) | No | Yes (n = 53) | No | Ritonavir-boosted (n = 15; 22.4%) |
Chiara, 2010 [44] | 2006-2009 | No | Yes (n = 10) | NR | NR | Yes (n = 15) | NR | Ritonavir-boosted (n = 15; 100%) |
Peterson 2011 [18] | 2004-2009 | NR | NR | Yes [46] | No | No | No | Ritonavir-boosted PI (n = 45, 100%) |
Benard, 2011 [15] | 1998-2008 | No | Yes (n = 44) | Yes (n = 76) | No | Yes (n = 18) | Yes (n = 16) | Ritonavir-boosted PI (n = 126) |
Peterson, 2012 [45] | NR | Yes (n = 0) | No | Yes (n = 1) | Yes (n = 2) | Yes (n = 1) | Yes (n = 0) | One patient on raltegravir as first-line regimen |